Drugs / 2B3-101
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01386580 | Jul 2011 → Dec 2014 | breast cancer, lung cancer, malignant glioma, melanoma +1 | BBB-Therapeutics B.V. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01818713 | Oct 2013 → Oct 2014 | neoplastic meningitis | The Netherlands Cancer Institute | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2B3-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01818713 ↗ |
| Route | Intravenous | “Patients will receive a single IV dose of 2B3-101 on day 1 of each cycle.” NCT01386580 ↗ |